Sigma Pharmaceuticals Posts US$357mn Net Loss

It is BMI's view that the almost 50% decrease in Australian firm Sigma Pharmaceuticals's share price can be attributed to over-optimistic forecasting. Following its US$2.2bn merger with compatriot company Arrow Pharmaceuticals, Sigma believed the combined entity could maintain the steep sales growth trajectory established in preceding years.

To read the full article, please choose one of the following options: